Overview of Sunstone Health

Sunstone’s platform operates across three integrated stages:
Stage One — Intelligent Claims Surveillance. Sunstone’s AI engine ingests existing health insurance claims data from the employer’s Third Party Administrator (TPA) — data the employer already owns but has rarely leveraged for clinical intelligence. The model identifies combinations of diagnosis codes, utilization patterns, specialist referrals, and billing sequences that correlate with undiagnosed rare or genetic conditions. No new data collection is required. No disruption to existing benefit workflows.
Stage Two — Precision Care Coordination. When the surveillance engine flags a high-probability member, Sunstone initiates a structured care pathway: outreach to the family, facilitation of whole-genome sequencing (through a contracted partnership with Broad Clinical Labs), specialist review by clinical geneticists and subspecialists, and synthesis into a comprehensive care plan. The model is clinician-to-clinician — AI serves as the intelligence infrastructure that makes the clinical professional extraordinarily effective, not as a replacement for human judgment.
Stage Three — Outcomes Delivery and Reporting. Sunstone closes the loop with confirmed diagnoses and actionable care plans, then delivers employer-facing outcomes reporting demonstrating both clinical and financial impact. For autism and developmental conditions, the platform extends further: ABA therapy management through outcomes-indexed utilization management, dual-coverage coordination (Katie Beckett, Part C Early Intervention, Medicaid as secondary payer), and continuous outcomes reviews at 90-day intervals.
What typically takes seven years of diagnostic wandering is compressed to twelve weeks.

Sunstone’s impact operates at three levels simultaneously.
For families, the platform ends the diagnostic odyssey. Children identified early receive whole-genome sequencing, specialist-level review, and a confirmed diagnosis — along with a care plan calibrated to their specific genetic subtype, not a population average. Earlier diagnosis means access to earlier intervention, better developmental trajectories, and reduced lifetime care burden.
For employers, the financial impact is structural. The average employer plan savings per identified case is approximately 60% compared to the unmanaged trajectory. The five-year cost waterfall per child — accounting for Early Intervention, Katie Beckett Medicaid coordination, and outcomes-based ABA utilization management — projects net savings exceeding $320,000 per child relative to the unmanaged baseline. At a plan-wide level, rare and genetic diseases represent the single most persistent and least-managed cost driver in self-funded benefits.
For the healthcare system, Sunstone represents a fundamental architectural shift. By sitting upstream of the therapeutic decision — before the diagnosis is confirmed, before the specialty drug is prescribed, before the stop-loss carrier enters the picture — the platform creates the identification layer that makes precision medicine accessible at the population level, within the employer benefit infrastructure that covers most Americans.
The innovation is not any single capability. It is the integration of claims-based AI surveillance, whole-genome sequencing logistics, physician-to-physician clinical guidance, and outcomes-indexed care management into a single, results-based platform that no competitor has assembled.

Sunstone serves two interconnected audiences:
Primary commercial customers — self-funded employers. The immediate buyer is the self-funded employer: specifically, the VP of Benefits, Chief People Officer, or CFO at mid-market to large employers (typically 1,000–50,000+ covered lives). The go-to-market pipeline segments these buyers into “Fast Transactors” (mid-market, 3–9 month sales cycles, financial services, tech, and professional services verticals) and “White Whales” (Fortune 1000 enterprises, 9–18+ month sales cycles, typically accessed through consultants, TPAs, or Blue Cross affiliates).
Secondary distribution channels — TPAs and stop-loss carriers. These are natural distribution partners and, increasingly, natural co-sellers: they benefit directly from earlier diagnosis, reduced catastrophic claims exposure, and attachment point breach prevention. The National Alliance TPA distribution play — currently in development with BCBS SC via Trey Hinson — and the Florida Blues relationship represent the near-term expression of this channel strategy.
Ultimate beneficiaries — children and families. The downstream beneficiaries of every employer contract are the children and families whose diagnostic odyssey Sunstone shortens. This dual-audience structure — employer as payer/customer, family as beneficiary — is central to Sunstone’s mission and its market narrative.

Sunstone’s partnership architecture is both active and expansive:
Whole-Genome Sequencing Laboratories. Broad Clinical Labs is fully contracted as Sunstone’s primary sequencing partner, providing the clinical-grade WGS infrastructure that underpins the care pathway. This relationship is a structural differentiator — not a vendor arrangement, but a clinical partnership that integrates seamlessly into the employer benefit workflow.
TPA and Stop-Loss Distribution. The platform’s zero-setup-fee, pay-for-performance model is purpose-built for TPA and stop-loss integration. Sunstone is pursuing a TPA distribution strategy through the National Alliance, with Publix as the targeted initial pilot account via the BCBS SC CMIO relationship. Stop-loss carriers represent a parallel embedded-benefit opportunity: Sunstone reduces their attachment-point breach probability and fits naturally as a preferred-pricing incentive for plan sponsors.
Blue Cross Blue Shield Affiliates. Warm senior-level relationships at Florida Blues and an active channel through BCBS SC’s CMIO represent near-term partnership development targets with significant scale potential.
Specialty Pharma and Life Sciences. As Sunstone’s case library grows, the platform’s upstream position — identifying patients before specialty drug prescriptions are written — creates natural partnership and data-licensing opportunities with pharmaceutical companies developing therapies for conditions on the expansion roadmap.
Clinical Networks and Health Systems. The Sunstone Clinical PC structure (in formation) enables direct clinical network partnerships, ACO relationships, and population health management contracts with health systems seeking to improve developmental outcomes for attributed pediatric populations.
Brokers and Benefits Consultants. Progressive broker relationships are the highest-leverage GTM investment for employer channel development. A single well-positioned broker can introduce 10+ employer clients. Building relationships with 2–3 innovative broker firms in parallel with direct employer sales is a near-term priority.

Current round — Series A close. Sunstone is currently completing its Series A, with $1M remaining to close the round. The pre-money valuation is $8.5M (set by Saturn Partners), with 1x preference. The use of proceeds is focused on executing active pilots and expanding operational capacity to serve enterprise customers entering the January 1, 2027 enrollment window. The company has approximately $900K cash on hand and ~$100K monthly burn, with five post-NDA commercial conversations active.
Near-term — Series A extension ($10–20M). The planned Series A extension — to be raised as commercial traction from the current pilot pipeline converts into contracted employer lives — is targeted at three value-creation levers: (1) commercial infrastructure, including CCO hire and enterprise sales buildout calibrated to the 1/1/27 enrollment cycle; (2) platform expansion, extending condition coverage from autism and pediatric epilepsy to cardiometabolic disorders, neuromuscular disease, and broader CNS conditions; and (3) data asset development, deepening the proprietary case library that compounds Sunstone’s surveillance accuracy and competitive moat with each confirmed diagnosis.
Longer-term capital trajectory. The Series B ($20–50M, target 2028–2029) supports national scale: 20–50+ contracted employer clients, multi-state clinical network expansion through the MSO-PC structure, published clinical outcomes studies, and HITRUST certification. The long-term vision — becoming the identification and intelligence layer for the $80–100B genetic disease specialty pharmaceutical market — positions Sunstone as a platform that directs the most expensive drugs in the benefit ecosystem on behalf of the employers paying for them.